Cancer cells are malignant tumor cells derived from epithelial cells, which have the characteristics of infinite proliferation, transformation and easy transfer. Recently, scientists have found
Structure is the key to achieving functionality. The structure of an ADC is obvious: antibody, linker, and coupled drug. Whether an ADC is successful or
Breast cancer is the most common cancer and one of the leading causes of cancer-related deaths worldwide. In 2020, more than 2 million cases of
The physicochemical properties of toxins directly affect the ability of ADCs to kill target cells. Therefore, ADC cytotoxins usually have the following characteristics:(1) The mechanism
The target identification of ADC drugs plays a decisive role in the drugability of ADCs. Qualified ADC targets should have:(1) Tissue specificity: In order to
I. INTRODUCTION This guidance provides recommendations to assist industry in the development of oligonucleotide therapeutics under section 505 of the Federal Food, Drug, and Cosmetic
The first generation: represented by Mylotarg, with high off-target toxicity and low drug efficacy Mylotarg It is the world’s first marketed ADC drug, the first
On June 23, Xinghand Bio announced that the company first announced its targeting hepatitis B virus surface antigen (HBsAg) at the 57th European Association for
On June 24, BMS announced that the FDA approved a new indication of the CD19 CAR-T therapy Breyanzi (lisocabtagene maraleucel) for the second-line treatment of
1. Pfizer: Pioneer in the field of ADC, launched the world’s first ADC drug Mylotarg Mylotarg (Gemtuzumabozogamicin, gemtuzumab) was originally developed by Pfizer. It is
On June 22, several Japanese media, including the Mainichi Shimbun, reported that Shionogi’s S-217622 emergency authorization application based on Phase II data was suspended by
1. Selection of the correct target The successful development of ADC relies on the specific binding of antibodies to the target antigen. The ideal ADC
